EPHA2 and cancer: Notably, the same study demonstrated that a combined targeting of FAP+ CAFs and EPH receptor A2 (EphA2)+ cancer cells led to a nearly complete remission of the tumors [125], suggesting that CAF or PSC targeting can synergize with cancer-cell killing.